Ionis Pharmaceuticals (FRA:ISI) Research & Development: €794.7 Mil (TTM As of Mar. 2026)


FRA:ISI Ionis Pharmaceuticals Inc FRA:ISI
65 GF Score
Price €71.72
GF Value €47.81
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Ionis Pharmaceuticals Research & Development?

Ionis Pharmaceuticals FRA:ISI +6.44% 65 Research & Development is €794.7 Mil as of Mar. 2026. GuruFocus rates FRA:ISI with a GF Score™ of 65/100 and a GF Value™ of €47.81 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Ionis Pharmaceuticals's Research & Development for the three months ended in Mar. 2026 was €181.8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was €794.7 Mil.

Ionis Pharmaceuticals  (FRA:ISI) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Ionis Pharmaceuticals Research & Development Related Terms

Ionis Pharmaceuticals Research & Development Historical Data

* Premium members only.

The historical data trend for Ionis Pharmaceuticals's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ionis Pharmaceuticals Research & Development Chart

Ionis Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 569.46 786.49 824.96 860.96 781.94

Ionis Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 185.70 188.54 185.53 238.82 181.80
FRA:ISI
65GF Score
Ionis Pharmaceuticals Inc FRA:ISI
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ionis Pharmaceuticals Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €794.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €794.7 Mil mean?
Ionis Pharmaceuticals (FRA:ISI) has a Research & Development of €794.7 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Ionis Pharmaceuticals and its competitors.
Is Ionis Pharmaceuticals' Research & Development too high?
Ionis Pharmaceuticals' current Research & Development is €794.7 Mil. Overall, Ionis Pharmaceuticals has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Ionis Pharmaceuticals' Research & Development compare to EXEL and BBIO?
Ionis Pharmaceuticals' Research & Development of €794.7 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Ionis Pharmaceuticals and its competitors. Ionis Pharmaceuticals's current Research & Development is €794.7 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ionis Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Ionis Pharmaceuticals (FRA:ISI) is currently considered Significantly Overvalued. The stock's GF Value™ is €47.81, compared to a current price of €71.72 — trading 50% above its estimated fair value. The current Research & Development is €794.7 Mil. Ionis Pharmaceuticals' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Ionis Pharmaceuticals (FRA:ISI), the current Research & Development is €794.7 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ionis Pharmaceuticals (FRA:ISI) Overvalued in 2026?

Based on GuruFocus' analysis, Ionis Pharmaceuticals stock appears to be overvalued. The current stock price of €71.72 is trading 50% above its estimated GF Value™ of €47.81. GuruFocus considers Ionis Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for FRA:ISI:

  • Research & Development: €794.7 Mil
  • GF Value™: €47.81 vs. price of €71.72 (50% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the FRA:ISI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ionis Pharmaceuticals Business Description

Other Exchanges IONS:USA1IONS:Italy0JDI:UK
Address 2855 Gazelle Court, Carlsbad, CA, USA, 92010
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).
65GF Score

Get the complete analysis for FRA:ISI

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€71.72
Price
€47.81
GF Value